Skip to content

Study · Randomized controlled trial · n = 104 · 2024

7 results

Liraglutide treatment for the prevention of glucose tolerance deterioration in women with prior gestational diabetes mellitus: A 52-week randomized controlled clinical trial.

Foghsgaard S, Vedtofte L, Andersen ES, Bahne E, Andreasen C, Sørensen AL, Forman JL, Mathiesen ER, Svare JA, Clausen TD, Damm P, Holst JJ, Knop FK, Vilsbøll T

Diabetes, obesity & metabolism17 Oct 2023Cited by 17 (Europe PMC)

PMID37846555 (opens in a new tab)DOI10.1111/dom.15306 (opens in a new tab)PepBankPUB-37846555
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In women with overweight/obesity and previous gestational diabetes, liraglutide reduced the OGTT glucose area under the curve versus placebo at 52 weeks.

    In plain wordsIn women with overweight or obesity and past gestational diabetes, liraglutide lowered blood glucose after a sugar drink more than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseArea under the curve during OGTT
    Study

    n = 104

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.8 mg once daily · subcutaneous · 52 weeksAs given in this study (human).

    Measurements

    ETD AUC OGTT
    −173 mmol/L × min
    liraglutide vs placebo

    Source sentences

    Summary
    Estimated treatment difference (ETD) for area under curve during OGTT was -173 (95% confidence interval -250 to -97) mmol/L × min, p < .0001
    1 context sentence
    Summary · context
    Women with overweight/obesity and pGDM were randomized to once daily subcutaneous liraglutide 1.8 mg or placebo for 52 weeks.
  2. 02HumanRandomized controlled trialEfficacy outcome

    After drug wash-out, the OGTT area under the curve no longer differed between liraglutide and placebo.

    In plain wordsAfter liraglutide was stopped, the glucose benefit disappeared compared with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeArea under the curve during OGTT after wash-out
    Study

    n = 104

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.8 mg once daily · subcutaneous · 52 weeksAs given in this study (human).

    Measurements

    ETD AUC OGTT after wash-out
    58 mmol/L × min
    liraglutide vs placebo

    Source sentences

    Summary
    but after wash-out the difference disappeared [ETD 58 (-30 to 146) mmol/L × min, p = .536]
    1 context sentence
    Summary · context
    Women with overweight/obesity and pGDM were randomized to once daily subcutaneous liraglutide 1.8 mg or placebo for 52 weeks.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In women with overweight/obesity and previous gestational diabetes, liraglutide reduced fasting plasma glucose versus placebo.

    In plain wordsIn women with overweight or obesity and past gestational diabetes, liraglutide lowered fasting glucose more than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseFasting plasma glucose
    Study

    n = 104

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.8 mg once daily · subcutaneous · 52 weeksAs given in this study (human).

    Measurements

    ETD FPG
    −0.2 mmol/L
    liraglutide vs placebo

    Source sentences

    Summary
    Liraglutide reduced FPG [ETD -0.2 (-0.4 to -0.1) mmol/L, p = .018]
    1 context sentence
    Summary · context
    Women with overweight/obesity and pGDM were randomized to once daily subcutaneous liraglutide 1.8 mg or placebo for 52 weeks.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In women with overweight/obesity and previous gestational diabetes, liraglutide reduced HbA1c versus placebo.

    In plain wordsIn women with overweight or obesity and past gestational diabetes, liraglutide lowered HbA1c more than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c
    Study

    n = 104

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.8 mg once daily · subcutaneous · 52 weeksAs given in this study (human).

    Measurements

    ETD HbA1c
    −2.2 mmol/mol
    liraglutide vs placebo

    Source sentences

    Summary
    Liraglutide reduced FPG [ETD -0.2 (-0.4 to -0.1) mmol/L, p = .018], HbA1c [-2.2 (-3.5 to -0.8) mmol/mol, p = .018] and bodyweight [-3.9 (-6.2 to -1.6) kg, p = .012].
    1 context sentence
    Summary · context
    Women with overweight/obesity and pGDM were randomized to once daily subcutaneous liraglutide 1.8 mg or placebo for 52 weeks.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In women with overweight/obesity and previous gestational diabetes, liraglutide reduced body weight versus placebo.

    In plain wordsIn women with overweight or obesity and past gestational diabetes, liraglutide lowered body weight more than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight
    Study

    n = 104

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.8 mg once daily · subcutaneous · 52 weeksAs given in this study (human).

    Measurements

    ETD body weight
    −3.9 kg
    liraglutide vs placebo

    Source sentences

    Summary
    Liraglutide reduced FPG [ETD -0.2 (-0.4 to -0.1) mmol/L, p = .018], HbA1c [-2.2 (-3.5 to -0.8) mmol/mol, p = .018] and bodyweight [-3.9 (-6.2 to -1.6) kg, p = .012].
    1 context sentence
    Summary · context
    Women with overweight/obesity and pGDM were randomized to once daily subcutaneous liraglutide 1.8 mg or placebo for 52 weeks.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In women with overweight/obesity and previous gestational diabetes, liraglutide did not change the incretin effect.

    In plain wordsIn women with overweight or obesity and past gestational diabetes, liraglutide did not change the gut-hormone (incretin) effect.

    Peptide
    Liraglutide
    Outcome
    No significant changeIncretin effect
    Study

    n = 104

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.8 mg once daily · subcutaneous · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    No change in the incretin effect was observed.
    1 context sentence
    Summary · context
    Women with overweight/obesity and pGDM were randomized to once daily subcutaneous liraglutide 1.8 mg or placebo for 52 weeks.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In women with overweight/obesity and previous gestational diabetes, prediabetes fell from 64% to 10% with liraglutide versus 50% with placebo.

    In plain wordsIn women with overweight or obesity and past gestational diabetes, prediabetes fell from 64% to 10% with liraglutide versus 50% with placebo.

    Peptide
    Liraglutide
    Outcome
    DecreasePrevalence of prediabetes
    Study

    n = 104

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.8 mg once daily · subcutaneous · 52 weeksAs given in this study (human).

    Measurements

    Prediabetes prevalence
    10%
    liraglutide at 52 weeks
    Prediabetes prevalence
    50%
    placebo
    Adjusted odds ratio
    0.1
    liraglutide vs placebo

    Source sentences

    Summary
    The number of women with prediabetes was reduced from 64% to 10% with liraglutide vs. 50% with placebo [adjusted odds ratio 0.10 (0.03-0.32), p = .002].
    1 context sentence
    Summary · context
    Women with overweight/obesity and pGDM were randomized to once daily subcutaneous liraglutide 1.8 mg or placebo for 52 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.